(Fontolizumab)Biosimilar Reference Antibody-GS40274

货号：GS40274

Fontolizumab was an investigational, humanized monoclonal antibody developed for the treatment of inflammatory and autoimmune diseases, particularly Crohn's disease. It functioned as a targeted interferon-gamma (IFN-γ) inhibitor. By binding to and neutralizing IFN-γ in the bloodstream, fontolizumab aimed to suppress the activity of this key pro-inflammatory cytokine, which is central to the Th1-mediated immune response implicated in the pathogenesis of Crohn's disease. The goal was to reduce the excessive inflammation in the intestinal tract and induce clinical remission.